
γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
CIO of Prime Therapeutics, Jim Graham, discusses with MHE how to successfully reach digital transformation in healthcare from a traditional PBM.





